Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells

Benedikt Warth, Amelia Palermo, Nicholas J.W. Rattray, Nathan V. Lee, Zhou Zhu, Linh T. Hoang, Yuping Cai, Anthony Mazurek, Stephen Dann, Todd VanArsdale, Valeria R. Fantin, David Shields, Gary Siuzdak, Caroline H. Johnson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic pathways are targeted during these different modes of treatment. Individually, the drugs caused metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was observed when the drugs were applied together, confirming the combinatory therapy’s synergism in the cell model. This study also highlights the power of merging high-dimensional datasets to unravel mechanisms involved in cancer metabolism and therapy.

LanguageEnglish
Article number7
Number of pages15
JournalMetabolites
Volume9
Issue number1
DOIs
Publication statusPublished - 2 Jan 2019

Fingerprint

Metabolism
Cyclin-Dependent Kinase 6
Carbon
Cells
Cyclin-Dependent Kinase 4
Breast Neoplasms
Metabolic Networks and Pathways
Pentoses
Chemotherapy
Coenzymes
Merging
Pharmaceutical Preparations
Pentose Phosphate Pathway
Phosphates
MCF-7 Cells
Combination Drug Therapy
Disease-Free Survival
Therapeutics
Survival
fulvestrant

Keywords

  • breast cancer
  • combination drug therapy
  • metabolomics
  • multi-omics
  • RNA-seq
  • XCMS online

Cite this

Warth, Benedikt ; Palermo, Amelia ; Rattray, Nicholas J.W. ; Lee, Nathan V. ; Zhu, Zhou ; Hoang, Linh T. ; Cai, Yuping ; Mazurek, Anthony ; Dann, Stephen ; VanArsdale, Todd ; Fantin, Valeria R. ; Shields, David ; Siuzdak, Gary ; Johnson, Caroline H. / Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells. In: Metabolites. 2019 ; Vol. 9, No. 1.
@article{9196e9e509b44985948d04cacaa6b985,
title = "Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells",
abstract = "The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic pathways are targeted during these different modes of treatment. Individually, the drugs caused metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was observed when the drugs were applied together, confirming the combinatory therapy’s synergism in the cell model. This study also highlights the power of merging high-dimensional datasets to unravel mechanisms involved in cancer metabolism and therapy.",
keywords = "breast cancer, combination drug therapy, metabolomics, multi-omics, RNA-seq, XCMS online",
author = "Benedikt Warth and Amelia Palermo and Rattray, {Nicholas J.W.} and Lee, {Nathan V.} and Zhou Zhu and Hoang, {Linh T.} and Yuping Cai and Anthony Mazurek and Stephen Dann and Todd VanArsdale and Fantin, {Valeria R.} and David Shields and Gary Siuzdak and Johnson, {Caroline H.}",
year = "2019",
month = "1",
day = "2",
doi = "10.3390/metabo9010007",
language = "English",
volume = "9",
journal = "Metabolites",
issn = "2218-1989",
number = "1",

}

Warth, B, Palermo, A, Rattray, NJW, Lee, NV, Zhu, Z, Hoang, LT, Cai, Y, Mazurek, A, Dann, S, VanArsdale, T, Fantin, VR, Shields, D, Siuzdak, G & Johnson, CH 2019, 'Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells' Metabolites, vol. 9, no. 1, 7. https://doi.org/10.3390/metabo9010007

Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells. / Warth, Benedikt; Palermo, Amelia; Rattray, Nicholas J.W.; Lee, Nathan V.; Zhu, Zhou; Hoang, Linh T.; Cai, Yuping; Mazurek, Anthony; Dann, Stephen; VanArsdale, Todd; Fantin, Valeria R.; Shields, David; Siuzdak, Gary; Johnson, Caroline H.

In: Metabolites, Vol. 9, No. 1, 7, 02.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells

AU - Warth, Benedikt

AU - Palermo, Amelia

AU - Rattray, Nicholas J.W.

AU - Lee, Nathan V.

AU - Zhu, Zhou

AU - Hoang, Linh T.

AU - Cai, Yuping

AU - Mazurek, Anthony

AU - Dann, Stephen

AU - VanArsdale, Todd

AU - Fantin, Valeria R.

AU - Shields, David

AU - Siuzdak, Gary

AU - Johnson, Caroline H.

PY - 2019/1/2

Y1 - 2019/1/2

N2 - The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic pathways are targeted during these different modes of treatment. Individually, the drugs caused metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was observed when the drugs were applied together, confirming the combinatory therapy’s synergism in the cell model. This study also highlights the power of merging high-dimensional datasets to unravel mechanisms involved in cancer metabolism and therapy.

AB - The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic pathways are targeted during these different modes of treatment. Individually, the drugs caused metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was observed when the drugs were applied together, confirming the combinatory therapy’s synergism in the cell model. This study also highlights the power of merging high-dimensional datasets to unravel mechanisms involved in cancer metabolism and therapy.

KW - breast cancer

KW - combination drug therapy

KW - metabolomics

KW - multi-omics

KW - RNA-seq

KW - XCMS online

UR - http://www.scopus.com/inward/record.url?scp=85060004315&partnerID=8YFLogxK

U2 - 10.3390/metabo9010007

DO - 10.3390/metabo9010007

M3 - Article

VL - 9

JO - Metabolites

T2 - Metabolites

JF - Metabolites

SN - 2218-1989

IS - 1

M1 - 7

ER -